NASDAQ:NERV Minerva Neurosciences (NERV) Stock Forecast, Price & News $7.02 +0.39 (+5.88%) (As of 06/5/2023 ET) Add Compare Share Share Today's Range$6.66▼$7.0450-Day Range$1.60▼$7.7552-Week Range$1.26▼$15.27Volume109,507 shsAverage Volume193,698 shsMarket Capitalization$39.10 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Minerva Neurosciences MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside14.0% Upside$8.00 Price TargetShort InterestBearish6.41% of Float Sold ShortDividend StrengthN/ASustainability-0.89Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$192,503 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.14) to ($1.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.58 out of 5 starsMedical Sector863rd out of 986 stocksPharmaceutical Preparations Industry414th out of 476 stocks 2.0 Analyst's Opinion Consensus RatingMinerva Neurosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Minerva Neurosciences has a forecasted upside of 14.0% from its current price of $7.02.Amount of Analyst CoverageMinerva Neurosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.41% of the float of Minerva Neurosciences has been sold short.Short Interest Ratio / Days to CoverMinerva Neurosciences has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Minerva Neurosciences has recently increased by 263.45%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMinerva Neurosciences does not currently pay a dividend.Dividend GrowthMinerva Neurosciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMinerva Neurosciences has received a 71.85% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for Parkinsonism", "Clinical research services for schizophrenia", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Minerva Neurosciences is -0.89. Previous Next 1.1 News and Social Media Coverage Search Interest12 people have searched for NERV on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows2 people have added Minerva Neurosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Minerva Neurosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $192,503.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Minerva Neurosciences is held by insiders.Percentage Held by InstitutionsOnly 38.00% of the stock of Minerva Neurosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Minerva Neurosciences are expected to grow in the coming year, from ($2.14) to ($1.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Minerva Neurosciences is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Minerva Neurosciences is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Minerva Neurosciences (NASDAQ:NERV) StockMinerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson's disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.Read More Receive NERV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address NERV Stock News HeadlinesMay 30, 2023 | americanbankingnews.comMinerva Neurosciences (NASDAQ:NERV) Receives New Coverage from Analysts at StockNews.comMay 22, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV)June 6, 2023 | Behind the Markets (Ad)[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>May 19, 2023 | msn.comMinerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst AheadMay 18, 2023 | finance.yahoo.comWhat Makes Minerva Neurosciences (NERV) a New Buy StockMay 15, 2023 | benzinga.comMinerva Neurosciences Q1 2023 R&D Expenses $2.7M Vs $5M YoYMay 15, 2023 | finance.yahoo.comMinerva Neurosciences Reports 2023 First Quarter Financial Results and Business UpdatesMay 15, 2023 | msn.comMinerva Neurosciences GAAP EPS of -$1.31June 6, 2023 | Behind the Markets (Ad)[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>May 15, 2023 | finance.yahoo.comMinerva Neurosciences Reports 2023 First Quarter Financial Results and Business UpdatesMay 13, 2023 | americanbankingnews.comMinerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.comMay 10, 2023 | marketwatch.comMinerva Neurosciences Gets FDA Confirmation for NDA for RoluperidoneMay 8, 2023 | finance.yahoo.comMinerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023May 4, 2023 | americanbankingnews.comMinerva Neurosciences, Inc. (NASDAQ:NERV) CEO Remy Luthringer Sells 23,753 SharesMay 3, 2023 | benzinga.comMinerva Neurosciences Stock (NASDAQ:NERV), Guidance and ForecastMay 3, 2023 | benzinga.comMinerva Neurosciences Stock (NASDAQ:NERV), Short Interest ReportMay 3, 2023 | americanbankingnews.comMinerva Neurosciences, Inc. (NASDAQ:NERV) CFO Frederick W. Ahlholm Sells 3,580 Shares of StockMay 3, 2023 | americanbankingnews.comMinerva Neurosciences, Inc. (NASDAQ:NERV) President Geoff Race Sells 22,082 SharesMay 2, 2023 | markets.businessinsider.comMinerva Neurosciences (NERV) Receives a Hold from H.C. WainwrightMay 1, 2023 | marketwatch.comMinerva Neurosciences Shares Rise 25% FDA Files NDA for RoluperidoneMay 1, 2023 | finance.yahoo.comMinerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in SchizophreniaApril 27, 2023 | marketwatch.comInsomnia Medication Market Forecast to 2030April 27, 2023 | americanbankingnews.comMinerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.comApril 19, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV)April 3, 2023 | americanbankingnews.comMinerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.comMarch 10, 2023 | finance.yahoo.comMinerva Neurosciences, Inc. (NASDAQ:NERV) Q4 2022 Earnings Call TranscriptMarch 9, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Minerva Neurosciences (NERV) and Evolus (EOLS)See More Headlines NERV Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NERV Company Calendar Last Earnings3/08/2023Today6/06/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NERV CUSIPN/A CIK1598646 Webwww.minervaneurosciences.com Phone(617) 600-7373FaxN/AEmployees9Year Founded2007Price Target and Rating Average Stock Price Forecast$8.00 High Stock Price Forecast$8.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+14.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($5.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,110,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-50.67% Debt Debt-to-Equity RatioN/A Current Ratio14.66 Quick Ratio14.66 Sales & Book Value Annual Sales$41.18 million Price / Sales0.95 Cash FlowN/A Price / Cash FlowN/A Book Value($3.75) per share Price / Book-1.87Miscellaneous Outstanding Shares5,570,000Free Float5,262,000Market Cap$39.10 million OptionableOptionable Beta0.02 Social Links Key ExecutivesRémy Henri LuthringerExecutive Chairman & Chief Executive OfficerGeoff RacePresidentJoseph ReillyChief Operating Officer & Senior Vice PresidentFred AhlholmChief Financial Officer, Secretary & Senior VPMichael DavidsonChief Medical OfficerKey CompetitorsPurple BiotechNASDAQ:PPBTBullfrog AINASDAQ:BFRGNovanNASDAQ:NOVNYumanity TherapeuticsNASDAQ:YMTXAcurx PharmaceuticalsNASDAQ:ACXPView All CompetitorsInsiders & InstitutionsGroup One Trading L.P.Sold 54,900 shares on 5/12/2023Ownership: 0.000%Remy LuthringerSold 23,753 sharesTotal: $91,449.05 ($3.85/share)Geoff RaceSold 22,082 sharesTotal: $85,015.70 ($3.85/share)Frederick W AhlholmSold 3,580 sharesTotal: $16,038.40 ($4.48/share)View All Insider TransactionsView All Institutional Transactions NERV Stock - Frequently Asked Questions Should I buy or sell Minerva Neurosciences stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NERV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NERV, but not buy additional shares or sell existing shares. View NERV analyst ratings or view top-rated stocks. What is Minerva Neurosciences' stock price forecast for 2023? 2 Wall Street analysts have issued 1 year price objectives for Minerva Neurosciences' shares. Their NERV share price forecasts range from $8.00 to $8.00. On average, they expect the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 14.0% from the stock's current price. View analysts price targets for NERV or view top-rated stocks among Wall Street analysts. How have NERV shares performed in 2023? Minerva Neurosciences' stock was trading at $1.59 at the start of the year. Since then, NERV stock has increased by 341.5% and is now trading at $7.02. View the best growth stocks for 2023 here. Are investors shorting Minerva Neurosciences? Minerva Neurosciences saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 297,300 shares, an increase of 263.4% from the April 30th total of 81,800 shares. Based on an average daily volume of 180,800 shares, the days-to-cover ratio is currently 1.6 days. Currently, 6.4% of the company's shares are short sold. View Minerva Neurosciences' Short Interest. When is Minerva Neurosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our NERV earnings forecast. How were Minerva Neurosciences' earnings last quarter? Minerva Neurosciences, Inc. (NASDAQ:NERV) issued its quarterly earnings results on Wednesday, March, 8th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.35) by $0.09. When did Minerva Neurosciences' stock split? Minerva Neurosciences shares reverse split on the morning of Tuesday, June 21st 2022. The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What other stocks do shareholders of Minerva Neurosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD). What is Minerva Neurosciences' stock symbol? Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV." Who are Minerva Neurosciences' major shareholders? Minerva Neurosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Group One Trading L.P. (0.00%). Insiders that own company stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Heek G Jan Van, Joseph H Reilly and Remy Luthringer. View institutional ownership trends. How do I buy shares of Minerva Neurosciences? Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Minerva Neurosciences' stock price today? One share of NERV stock can currently be purchased for approximately $7.02. How much money does Minerva Neurosciences make? Minerva Neurosciences (NASDAQ:NERV) has a market capitalization of $39.10 million and generates $41.18 million in revenue each year. The biopharmaceutical company earns $-32,110,000.00 in net income (profit) each year or ($5.49) on an earnings per share basis. How can I contact Minerva Neurosciences? Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The official website for the company is www.minervaneurosciences.com. The biopharmaceutical company can be reached via phone at (617) 600-7373 or via email at wboni@minervaneurosciences.com. This page (NASDAQ:NERV) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.